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Abstract
One of the important lessons learned from the 2009 H1N1 pandemic is that a high yield in-
fluenza vaccine virus is essential for efficient and timely production of pandemic vaccines in
eggs. The current seasonal and pre-pandemic vaccine viruses are generated either by clas-
sical reassortment or reverse genetics. Both approaches utilize a high growth virus, gener-
ally A/Puerto Rico/8/1934 (PR8), as the donor of all or most of the internal genes, and the
wild type virus recommended for inclusion in the vaccine to contribute the hemagglutinin
(HA) and neuraminidase (NA) genes encoding the surface glycoproteins. As a result of ex-
tensive adaptation through sequential egg passaging, PR8 viruses with different gene se-
quences and high growth properties have been selected at different laboratories in past
decades. The effect of these related but distinct internal PR8 genes on the growth of vac-
cine viruses in eggs has not been examined previously. Here, we use reverse genetics to
analyze systematically the growth and HA antigen yield of reassortant viruses with 3 differ-
ent PR8 backbones. A panel of 9 different HA/NA gene pairs in combination with each of
the 3 different lineages of PR8 internal genes (27 reassortant viruses) was generated to
evaluate their performance. Virus and HA yield assays showed that the PR8 internal genes
influence HA yields in most subtypes. Although no single PR8 internal gene set outper-
formed the others in all candidate vaccine viruses, a combination of specific PR8 backbone
with individual HA/NA pairs demonstrated improved HA yield and consequently the speed
of vaccine production. These findings may be important both for production of seasonal vac-
cines and for a rapid global vaccine response during a pandemic.
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Introduction
Vaccination is the major medical intervention to mitigate the public health impact of illness
due to influenza. The majority of the seasonal influenza vaccines produced globally are triva-
lent inactivated products that are manufactured in large scale by propagating selected high-
growth reassortant (HGR) viruses in embryonated chicken eggs. Virions are subsequently
chemically inactivated, purified and generally split into subviral antigens which are formulated
with or without adjuvants and dispensed into multi-dose vials or individual syringes [1]. The
complexity of the fertile egg supply chain and the specialized manufacturing facility require-
ments limit options to expand production in response to a pandemic, underscoring the critical
importance of maximizing the productivity of HGRs used in the current manufacturing pro-
cesses. Because the success of vaccination depends on immunizing the population before the
new virus spreads widely [2,3,4], rapid pandemic vaccine development, manufacturing and de-
livery are essential.
The qualitative and quantitative growth characteristics of the HGR vaccine virus seeds used
in manufacturing are widely recognized as major determinants of the number of vaccine doses
obtained from each egg [5]. Most wild-type seasonal influenza viruses encoding the recom-
mended HA and NA antigens for immunization grow poorly in eggs even after sequential pas-
sages in the laboratory [6]. In the late 1960's, Kilbourne et al. [7] mitigated this problem by
exploiting the exceptional replication efficiency of the laboratory-adapted A/Puerto Rico/8/
1934 (PR8) virus in eggs through genetic reassortment [6]. This technique is used to produce
viruses containing the surface genes (HA and NA) from the epidemic/pandemic virus of inter-
est and most of the "internal genes" (PB1, PB2, PA, NP, M, NS) from PR8; such reassortants
generally have virus yields exceeding those of the parental wild-type virus donor. These candi-
date vaccine viruses (CVV) are designated as high growth reassortant (HGR) or, when appro-
priate, 6:2 genotype reassortant (6:2R) viruses. Although efficient replication of HGR viruses in
eggs is a multi-genic trait involving surface (HA and NA) as well as internal genes, the M gene
of the PR8 donor is invariably required [8].
Most of the inactivated seasonal influenza vaccines manufactured since the early 1980's uti-
lize PR8-derived HGR viruses [5], generally with 6:2 genotypes, for production of the type A
components. Several laboratories developing HGR viruses for vaccine production have used
different lineages of PR8 viruses, with distinct nucleotide and amino acid polymorphisms aris-
ing as a consequence of diverse passage histories [9] which may impact the antigen yields of
HGR viruses in manufacturing. Furthermore, HA antigen yields from 6:2R viruses with HA
and NA genes from influenza viruses of avian or swine origins have been highly variable and
frequently fall below the acceptable range for manufacturing vaccine in eggs, which is generally
no less than 10 mg of total viral proteins from the allantoic fluid of 100 eggs [10,11]. Complex
influenza virus phenotypes, such as replication in chicken embryos, are invariably determined
by multiple genetic loci that encode critical functions such as virus attachment to receptors and
entry into host cells (encoded mainly by the HA and NA genes) as well as gene expression and
genome replication (encoded by the 6 internal genes) [12,13,14,15,16,17]. Functional compati-
bility between HA and NA is critical to achieve efficient replication in the target host. Likewise,
compatibility among replicase/transcriptase genes and accessory genes (M and NS) is essential
for efficient virus growth. Although these two functional units operate somewhat autonomous-
ly, there is evidence of genetic interactions between these two broadly defined functions
[12,13,14,15,16,17]. Conducting a detailed analysis of the functional properties of available
PR8 internal gene donors and the most relevant HA-NA gene subtype/lineage combinations is
necessary to determine whether certain gene combinations can impart high growth in eggs.
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In this study, we selected three different PR8 virus lineages which have been used as the do-
nors of internal genes for development of reassortant seasonal and pre-pandemic candidate
vaccine viruses by WHO Influenza Collaborating Centers or Essential Regulatory Laboratories
[9,14,18,19,20]. We evaluated the growth (yield) characteristics of different lineages of PR8
donor viruses when combined with surface genes from a wide range of potentially pandemic vi-
ruses to inform rapid development of HGR viruses with the highest possible antigen yields in
eggs. To this end, we analyzed the viral antigen yield of three lineages of PR8 donor viruses
with HA and NA genes from nine viruses that represent divergent North American and Eur-
asian lineages of viruses from avian, swine and human hosts. Our findings have important im-
plications for strengthening vaccine preparedness to achieve effective pandemic mitigation.
Materials and Methods
Origin of influenza virus genes used to generate reassortant viruses
Influenza A viruses were used as donors of HA, NA and internal genes (Tables 1 and 2).
Generation and sequence analysis of reassortant viruses by reverse
genetics
Reassortant viruses were generated from plasmids by a reverse genetics approach. The viral
cDNAs were cloned into a plasmid vector under control of the human polymerase I promoter
and the mouse RNA polymerase I terminator (herein pPolI vector). Reverse genetics plasmids
encoding HA and NA surface genes and 6 internal genes were transfected into HK 293T cells
using Lipofectamine 2000 (Life Tech). For hemagglutinin genes derived from H5N1 highly
pathogenic virus, including A/Vietnam/1203/2004 and A/Hubei/1/2010, overlapping PCR mu-
tagenesis was performed to remove the polybasic amino acid. Viruses derived by plasmid trans-
fection of HK293 cells were propagated in 10–11 day old embryonated eggs and incubated at
35–37°C for 48 hrs. H1N1pdm, H5N1, and H7N9 CVV with PR8-A were generated for pan-
demic preparedness purposes[56].
Mutations in the HA genes were introduced by site directed mutagenesis (QuikChange
Multi Site-directed Mutagenesis Kit: Agilent Technologies; Santa Clara, CA) and confirmed by
sequence analysis.
Total RNA was extracted from allantoic fluid using the QiAmp Viral RNA minikit (Qiagen;
Valencia, CA) and reverse transcribed to cDNA and amplified using a one-step reaction system
(One step RT-PCR kit: Qiagen) and sequence specific primers. Sequence analysis of the result-
ing DNA amplicons served as templates for automated sequencing on an Applied Biosystems
3130 genetic analyzer, using cycle sequencing dye terminator chemistry (BigDye terminator
v3.1 cycle sequencing kit; Life Tech).
Morphologic analysis by EM
Reassortant viruses in allantoic fluid were fixed in 2.5% paraformaldehyde and prepared for
NSEM. For each virus sample, 2 μl was pipetted onto a 1% alcian blue treated formvar-carbon
coated 300 mesh nickel grid (Electron Microscopy Sciences). Samples were incubated over-
night on grids in a refrigerator at 4°C. Following overnight incubation, samples were blotted,
rinsed with 1% bacitracin (Gregory & Pirie, 1973), blotted and stained with 5% ammonium
molybdate [pH 6.9] with 1% trehalose (w/v) (Harris et al., 2006). The stain was immediately
blotted after applying and grid was then allowed to air dry prior to viewing at the transmission
electron microscope (120 kV, BioTwin, FEI, Hillsboro, OR)[57,58]. For each 6:2R sample, the
maximum and minimum diameters (nm) of 250 influenza virions were measured using AMT
A/PR/8/34 Imparting High Yields for Vaccine Production
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software (Advanced Microscopy Techniques, Corp.). Measurements were imported into
Microsoft Excel to calculate the number of spherical and non-spherical virions based on the
measured maximum diameter to minimum diameter ratio.
Virus propagation in eggs and concentration
All of the reassortant viruses were grown in 10–11 day-old embryonated hens’ eggs at 35–37°C
for 48 hrs (~62 hrs for H7N9 virus). Allantoic fluid was harvested from the chilled eggs and
clarified at 15,180 g for 10 min at 4°C (Sorvall SLA-1500 rotor). The supernatant was collected
and inactivated with ß-propiolactone (BPL) for approximately 24 hrs at 4°C before further pu-
rification. The inactivated virus was pelleted by centrifugation at 38,890 g for 3 hrs at 4°C (Sor-
vall A621 rotor). Virus pellets were resuspended overnight in phosphate buffered saline pH
7.40 (PBS) and loaded onto a 30%/55% sucrose gradient. The gradient was centrifuged at
90,235 g (Sorvall AH629 rotor) for 14hrs. The virus fractions were harvested and further pel-
leted at 131,101 g for 2.5 hrs. Each virus was propagated and purified at least twice
Table 1. Amino acid variation among viral proteins encoded by the PR8 internal genes.†
Gene Amino acid Backbone-A Backbone-B Backbone-C
PB2 105 M I I
251 K R R
299 K R R
360 S Y Y
504 V I I
702 R K K
PB1 175 K N N
205 I M M
208 R K K
216 G S S
563 R I R
PB1-F2 59 K R R
60 Q R R
PA 158 R K K
550 L I I
PA-x 158 R K K
212 A V A
NP 116 I I M
353 V L L
425 V I I
430 T N N
M2 27 A T T
39 I T T
NS1 23 V A A
55 E K E
101 E D D
NS2 26 E E G
89 V I I
†References: [9,14,19]
doi:10.1371/journal.pone.0128982.t001
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independently using a different batch of eggs. The three viruses sharing HA and NA surface
genes were always analyzed as a set.
Quantification of viral proteins in concentrated viruses by BCA
Amicroplate Pierce BCA assay kit was used to measure the total protein content of the purified
virus concentrate. For each sample, NP40 was added to a final concentration of 0.25%. Bovine
serum albumin (BSA) provided in the kit was used for the standard curve, and absorbance was
read at 562 nm. The BCA assay was performed according to manufacturer’s instructions.
Quantification of HA by SDS-PAGE and densitometry analyses
Approximately 10 μg of each virus concentrate was deglycosylated with PNGaseF (New En-
gland Biolabs) according to the manufacturer’s instructions. The deglycosylated samples were
loaded on a 10% Bis-Tris precast NuPAGE polyacrylamide gel (Life Tech) and electrophoresed
in NuPAGE MOPS SDS running buffer under reducing conditions. Two-fold serially diluted
BSA was prepared and loaded on the same gel as the standards for quantitation of virus protein
bands. The protein gels were stained with colloidal Coomassie blue (Life Tech), imaged with an
ImageScanner III, and quantified using ImageQuant software (GE Healthcare). The HA pro-
tein content of each deglycosylated virus sample was calculated by comparison to the BSA stan-
dards with known quantities on the same gel.
Table 2. HA and NA genes utilized in reassortment with selected PR8 donors along with IDMS peptides used in this study.†
Virus name Subtype Lineage Host
Adaptation
























































avian VNTLTERSTQSAIDQITGK IQIDPVK SGYETFR
A/Shanghai/2/
2013
H7N9 Eurasian avian VNTLTERFVNEEALRSTQSAIDQITGKIQIDPVK IGESSDVLVTRFYALSQGTTIRVPNALTDDR
†Peptides used for NP quantitation by IDMS were LIQNSLTIER and GVFESLDEK, whereas M1 quantitation used EITFHGAK.
doi:10.1371/journal.pone.0128982.t002
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Quantification of HA, NP, and M1 by IDMS
Isotope dilution mass spectrometry (IDMS) was performed as described previously for quanti-
fication of HA and NA proteins in seasonal H3N2, H1N1pdm09 [59], avian H5N1 [60],
H7N9, H7N2, and H7N7 [61] strains in purified virus samples. These protocols were modified
to quantify the NP and M1 proteins of influenza A and influenza B viruses (manuscript in
preparation). Briefly, the IDMS method involves enzymatic digestion of viral proteins and the
specific detection of evolutionarily conserved target peptides. Once the target peptides are iden-
tified, a labeled analog of the peptide is synthesized by incorporating an amino acid proximate
to the C-terminus with 13C and 15N to generate a peptide that is heavier in mass than the native
target peptide as described previously [60]. The target peptides used for HA, NA, NP, and M1
are shown in Table 2. Tryptic digestion of the viral proteins was followed by separation of the
peptides on an Agilent 1200 Capillary LC system (Agilent, Santa Clara, CA) and analyzed on a
Thermo TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific, Waltham,
MA).
Statistical analyses
Data were analyzed by 1-way ANOVA with Fisher’s LSD post-hoc analysis using the JMP soft-
ware package (Version 10, SAS Inc.).
Results
Genetic analysis of three lineages of PR8 donor viruses
Three lineages of PR8 influenza viruses (PR8-A, PR8-B and PR8-C) used by global public
health laboratories to produce HGR viruses for vaccine manufacturing were selected for this
study (Table 1) [9,14,15,20,21,22]. The proteins encoded by the internal genes (PB2, PB1,
PB1-F2, PA, PA-X, NP, M1, M2, NS1 and NS2) revealed multiple amino acid differences be-
tween PR8-A and PR-B or PR8-C genes, whereas PR8-B and PR8-C were more similar to each
other (Table 1). The ten proteins encoded by the six internal genes of PR8-A differed from
those of PR8-B and PR8-C at 26 and 25 positions, respectively, but only 5 amino acid differ-
ences were noted between PR8-B and PR8-C (Table 1).
Virologic and morphologic analysis of 6:2 reassortant viruses
To evaluate the antigen yields of HGR viruses with the different PR8 lineages bearing a broad
range of HA and NA genes, multiple subtypes of Eurasian or North American lineages were se-
lected, including viruses of avian, swine and human origin (Table 2). PR8 6:2R viruses were
generated from reverse genetics plasmid sets comprising the wild-type HA and NA genes from
avian viruses or human seasonal viruses. Utilizing nine selected HA-NA gene pairs and three
lineages of PR8 donor viruses, a total of 27 reassortant viruses were generated by reverse genet-
ics, all with 6:2 genotypes. Efficient growth in eggs required HA mutations in several strains: A/
New York /18/2009 D222G, A/Hawaii/07/2009 H183L, A/Bangladesh/5071/2011 H156Q/
G186V/S219Y, and A/Indiana/10/2011 L194I, based on the sequences of parental viruses iso-
lated in eggs. Full genome sequences of the second egg passage of these 6:2R viruses recovered
from transfected cells indicated absence of coding changes in these viral genomes as compared
to the sequences of the cDNA cloned in plasmids.
The replicative properties of reassortant viruses were analyzed using the second egg passage
of plasmid DNA-transfected cell supernatants. All reassortant viruses replicated efficiently in
eggs, reaching infectious titers between 1.0 x 108 and 2.4 x 1010 EID50/ml (S1 Fig).
A/PR/8/34 Imparting High Yields for Vaccine Production
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Hemagglutinating unit (HAU) titers ranged from 128 to 4096, in overall agreement with the in-
fectivity results (S1 Fig).
Previous studies suggested that incompatibility between PR8 and very divergent HA-NA
genes may result in release of pleomorphic or filamentous virions [23,24,25,26,27] with unpre-
dictable impact on manufacturing steps such as filtration or centrifugation. To investigate the
possible impact of PR8 internal genes on virion morphology, allantoic fluid harvests from a
subset of five representative 6:2R viruses were analyzed by negative-stain electron microscopy
(NSEM) (Fig 1 and S2 Fig). The approximate percentage of spherical virions (defined as virions
whose ratio of maximum diameter (nm) to minimum diameter (nm) is between 1 and 1.5) ran-
ged from 41.5% to 91% on average for the 15 viruses analyzed (5 sets of surface genes with 3
different PR8 internal genes) (Fig 1). With the exception of A/Hawaii/7/2009 (H3N2) 6:2R, vi-
ruses with PR8-A internal genes yielded a consistently higher percentage of spherical particles
(overall mean 79.6%) as compared to PR8-B and PR8-C (43.8% and 54.6%, respectively)
(P<0.05) (Fig 1).
Viral protein yield of 6:2 reassortant viruses with selected PR8 internal
genes
Although infectivity and HA assay titers in allantoic fluids are informative to estimate 6:2R
virus performance in vaccine manufacturing, they are not definitive predictors of viral antigen
yield after chemical inactivation and purification methods used in production (e.g. ultracentri-
fugation and/or chromatography). To estimate the potential vaccine antigen yields under
manufacturing conditions, we evaluated HA content in inactivated virions concentrated from
Fig 1. Percentage of spherical virions from reassortant viruses. Reassortant viruses were propagated in embryonated eggs, fixed in 2.5%
paraformaldehyde and analyzed by NSEM. A total of 250 virus particles from each reassortant virus were analyzed. Virus particle with axial ratio <1.5 is
scored as spherical virion. Statistical significance was assessed as described in Materials and Methods (*, P < 0.05; **, P < 0.01).
doi:10.1371/journal.pone.0128982.g001
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allantoic fluid by differential and equilibrium ultracentrifugation in sucrose gradients. Previous
reports showed that the minimum total viral protein requirement for manufacturing is approx-
imately 10 mg/100 eggs [15]. In this study, the total virion protein yields from 6:2R viruses de-
termined by BCA ranged from a high of 27 mg/100 eggs to a low of 1.4 mg/100 eggs (Fig 2).
The A(H3N2)v, A(H7N2), and A/Bangladesh/5071/2011 (H3N2) viruses formed a cluster with
yields of>11 mg/100 eggs, exceeding the minimum yield required for manufacturing and
therefore were designated high antigen yield (HAY) viruses. In contrast, the remaining 6 virus-
es were characterized by total protein yields6.5 mg/100 eggs and were designated low antigen
yield viruses (LAY). The three HAY 6:2R viruses revealed that PR8-B derived viruses yielded
higher total protein than PR8-C viruses in 2/3 of instances (P<0.05) (Fig 2). In contrast, com-
parisons within LAY 6:2R virus sets revealed that yields from PR8-A viruses were often higher
than those of PR8-B viruses (3/6 6:2R sets with P<0.05) (Fig 2).
To further quantify the antigen yield of the 6:2R viruses, we analyzed the purified viruses by
isotope dilution mass spectrometry (IDMS) and SDS-PAGE/densitometry analysis. IDMS
quantification revealed clustering of viruses into HAY (>3.4 mg/100 eggs; H3N2 Bang.) and
LAY (<2.8 mg/100 eggs; H7N9) groups with almost the same distribution as determined by
total virion protein assays (Fig 3A). Similarly, the total HA content of 6:2R virions concentrates
determined by SDS-PAGE/densitometry (Fig 3B) ranged from<1.6 mg/100 eggs (H7N9) for
LAY viruses to>3.8 mg/100 eggs (H3N2 Bang.) among HAY viruses. The HA yields deter-
mined by SDS-PAGE assays were slightly lower than those obtained by IDMS, possibly due to
the lower basic amino acid content of influenza HA protein relative to BSA, resulting in de-
creased Coomassie blue stain uptake. However, the relative HA yields of viruses with different
PR8 backbones remained consistent across assays. Comparisons within LAY 6:2R sets revealed
that yields from PR8-A viruses were often higher than those of PR8-B viruses (3/6 6:2R sets
with P<0.05) and in some cases yields from PR8-C viruses also were higher than those of
PR8-B (P<0.05).
Fig 2. Total viral protein yields in virions concentrated from allantoic fluid. Reassortant viruses were propagated in embryonated eggs and purified from
allantoic fluid by sucrose density gradient ultracentrifugation. Each virus was propagated and purified at least twice independently using a different batch of
eggs. Total viral protein in purified virus samples was determined by BCA as described in Materials and Methods. Statistical significance: *, P < 0.05; **,
P < 0.01.
doi:10.1371/journal.pone.0128982.g002
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Relative HA content of concentrated virus samples
Previous reports demonstrated that the low antigen yield from A/Vietnam/1194/04 (H5N1)
NIBRG-14 reassortant virus in eggs was caused by inefficient incorporation of HA into virions
[13,28,29]. To address this question, we calculated the percentage of HA determined by IDMS
relative to total viral protein determined by BCA (Fig 4). The mean HA content of purified
virus samples ranged from 8.5% to 48.4%. The impact of PR8 on relative HA content was not
Fig 3. Total HA yield in virus concentrates determined by IDMS and SDS- PAGE/densitometer analysis. Reassortant viruses were propagated in
embryonated eggs and purified from allantoic fluid by sucrose density gradient ultracentrifugation. Each virus was propagated and purified at least twice
independently using a different batch of eggs. Total HA in concentrated virus samples was determined by IDMS (A) and SDS-PAGE/densitometry (B) as
described in Materials and Methods. Statistical significance: *, P < 0.05; **, P < 0.01.
doi:10.1371/journal.pone.0128982.g003
A/PR/8/34 Imparting High Yields for Vaccine Production
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statistically significant (Fig 4). The potential differences in HA incorporation into virions were
obscured by the combined variance of BCA and IDMS determinations. To investigate whether
virion HA content varied in relation to other proteins, we quantified amount of NP and M pro-
tein in concentrated viruses by IDMS using a custom set of synthetic isotopically labeled pep-
tides (Table 2) as internal standards, and calculated their HA/NP and HA/M1 ratios. The
highest HA/NP ratios for the LAY viruses were noted among PR8-A internal genes with
H7N9, H2N3, H5N1 and H1N1pdm09 surface genes (Fig 5A). Interestingly, a higher HA/M1
ratio is observed for the viruses with the internal genes derived from PR8-C (Fig 5B; H3N2v,
H7N2, H7N9, H2N3, and pdmH1N1). The increased ratio of HA/NP or HA/M1 for PR8-A
and PR8-C-derived viruses coincided with improved HA content and HA antigen yield, sug-
gesting a possible increased incorporation of HA antigen into virions.
Discussion
Candidate reassortant viruses developed to manufacture licensed vaccines for pandemic pre-
paredness or response are designed to meet two critical requirements: high antigen yield in
eggs and adequate biosafety. The latter is ascertained by reduction in virulence and/or trans-
missibility in animal models [30,31]. Reassortment between influenza A viruses with pandemic
potential and a PR8 donor virus has been adopted without exception because it imparts both
virulence attenuation and the highest known replication ability in embryonated eggs. Although
pathogenicity studies in mice and ferret models have established the safety of 6:2R viruses
evaluated to date [32], suboptimal antigen yield in eggs is not uncommon. The low antigen
yields of the A/California/7/2009 A(H1N1)pdm09 vaccine viruses caused delays in rapidly
manufacturing large quantities of vaccine, and thus in achieving effective vaccine coverage in
high-risk groups [10] and illustrated the magnitude of the challenge. The impact of low vaccine
antigen yields on the effectiveness of pandemic mitigation through vaccination [2,33] provided
Fig 4. Relative HA content of concentrated virus samples. The relative HA content of each reassortant virus was calculated based on the ratio of the HA
(determined by IDMS) to the total protein (determined by BCA). Statistical significance: (*, P < 0.05; **, P < 0.01).
doi:10.1371/journal.pone.0128982.g004
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a strong motivation for studies aimed at improving the generation of 6:2R viruses for rapid and
efficient vaccine manufacturing in eggs [34].
Understanding the performance of three different PR8 virus lineages upon reassortment
with nine HA-NA gene pairs representing diverse subtypes and lineages of high public health
significance would establish a baseline to inform future candidate vaccine development for
pandemic responses. The resulting panel of 27 viruses provided an opportunity to investigate
associations between surface and internal genes, and their antigen yields based on parameters
such as total viral protein or amount of HA antigen produced in eggs. A striking linkage be-
tween HA antigen yield and the source of HA-NA surface protein-coding genes was observed
regardless of the PR8 gene source, reaching up to 65-fold differences when comparing 0.15 mg
Fig 5. Ratio of viral protein from virions concentrated from allantoic fluid. The molar ratio of (A) HA/NP and (B) HA/M1 of the concentrated viruses. The
HA, NP and M yield of the viruses were determined by IDMS. Statistical significance: (*, P < 0.05; **, P < 0.01).
doi:10.1371/journal.pone.0128982.g005
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HA/100 eggs (by IDMS) from H5N1-Hubei to 9.5 mg HA/100 eggs from H7N2-NY, confirm-
ing previous reports [12,13,14,15,16,17,35]. The variability among HA antigen yields re-em-
phasized that virus surface genes are key determinants of viral growth in embryonated eggs, in
agreement with other lines of evidence, such as positive selection in the HA and NA of candi-
date vaccine viruses selected for increased yields in eggs [36,37,38,39]. In addition, closely relat-
ed HA-NA surface genes such as the two A(H3N2) and A(H5N1) viruses can impart
substantially different yields. Therefore, when available, parallel evaluation of several related
HA and NA genes from co-circulating viruses with equivalent antigenicity using rapid rescue
techniques might provide significant gains in antigen yield and accelerate the production of
vaccines to mitigate an emerging pandemic[40].
Previous studies have demonstrated the importance of PR8 internal genes for optimal repli-
cation of 6:2R viruses in eggs [9,28,41]. The association between the presence of specific PR8
internal genes and HA yields was most pronounced among the LAY 6:2R viruses, reaching 5-
to 7-fold differences in hemagglutinin yield by IDMS assays for H5N1-Hubei with internal
genes from PR8-A or C versus PR8-B (Fig 3A). Notably, the PR8 virus donor associated with
lowest antigen yields in LAY 6:2Rs (i.e. PR8-B in H5N1 or H2N3 reassortants) mediated the
best performance among the HAY 6:2R viruses, such as H7N2, H3N2v and H3N2 viruses, sug-
gesting that functional interactions between HA-NA and PR8 genes are mediated by mutually
exclusive elements in the viruses analyzed. This finding is consistent with several earlier studies
concluding that functional compatibility between HA-NA (so-called “surface genes”) and PR8
internal genes is an important determinant of antigen yield from reassortant viruses in eggs
[12,13,14,15,16,17,42,43]. Taken together, these results indicated that PR8 lineages A (or C)
impart the highest hemagglutinin yield for 6:2R virus with low initial antigen yields in eggs. Al-
ternatively, the PR8-B might provide superior hemagglutinin yield for other 6:2R viruses with
high growth characteristics.
Previous studies established that the final HA yield from a reassortant virus used in vaccine
manufacturing results not only from the quantity but also from the quality of virions produced
[1]. The efficiency and kinetics of virion assembly and release into the allantoic fluid is deter-
mined by cell entry, replication and budding leading to efficient spread within the allantoic sac.
The mean percentage HA determined by IDMS relative to total protein (BCA) in 6:2R virus
samples revealed smaller differences among the HAY viruses (26% to 52%) than among the
LAY counterparts (5% to 40%) (Fig 4). The 20–26% HA determined for A/Vietnam/1203/2004
6:2R in this study is comparable to that reported for the almost identical reassortant A/Viet-
nam/1194/2004 [44]. In contrast, the low HA content (~5–12%) of the A(H1N1)pdm09 and
A/Hawaii (H3N2) 6:2R viruses might seem to compromise viral infectivity but previous reports
suggested that virions with low HA content could support virus fusion and entry [45,46]. The
ratio of HA relative to NP and M1 of the 6:2R viruses quantified by IDMS provided a complex
set of results that will require further investigation to determine their significance as a parame-
ter for selection of optimized CVV for vaccine manufacture.
The native morphology of influenza virions includes spherical, elliptical, or filamentous par-
ticles (S2 Fig), depending on the virus isolate and the host system [26]. The impact of virion
morphology on the stability of particles during manufacturing is not well understood but vac-
cine manufacturers prefer candidate vaccine viruses that yield spherical particles [47]. Unstable
filamentous virions are produced as a result of mutations in the M2 cytoplasmic tail [48]. Our
electron microscopy studies evaluated virions fixed in the original allantoic fluid harvest to
avoid ultracentrifugation artifacts [49] but established a stringent cutoff to account for addi-
tional deformation resulting from mechanical forces acting during virus concentration and pu-
rification. Morphometric analysis of five 6:2R viruses revealed a broad range (42 to 91%) in the
proportion of spherical virions, but morphology was not associated with the HA-NA subtype
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of the viruses. In contrast, virion morphology was correlated with the origin of PR8 internal
genes (P<0.01). M1, M2 and NP proteins have been shown to affect the spherical/filamentous
morphology [27,43,50,51,52]. Although the 3 lineages of PR8 M genes encode M1 proteins
with identical amino acid sequences, their M2 proteins are different at two positions, whereas
their NPs vary at four positions. Further studies are needed to elucidate their possible contribu-
tions to variation in virion morphology and stability [48]. A recent report suggested a fitness
advantage for growth of spherical influenza viruses in embryonated eggs [50] although spheri-
cal virions were not required for high growth in eggs [50]. In our study, non-spherical virions
appeared to be correlated with the best yield from the HAY H3N2v and H3N2 6:2R viruses an-
alyzed. In contrast, the highest yields from LAY 6:2R viruses were observed among highly
spherical PR8-A viruses (e.g. Hubei/1/2010). Nevertheless, these studies indicated that a high
percentage of non-spherical particles (e. g.60%) is compatible with satisfactory yields of HA
from the A(H3N2)v PR8-B reassortant. However, antigen losses during filtration steps used in
some vaccine manufacturing processes remained to be determined since our virus purification
method did not include filtration.
Sequence analysis of the PR8 lineages indicated that the internal gene proteome of PR8-A
had 26 and 25 amino acid differences relative to PR8-B and PR8-C, respectively, in contrast to
only five amino acid differences between the latter two donors. These differences correlated
well with the HA yield results indicating distinct functional properties of PR8-A relative to the
other two PR8 donor viruses. Reassortment studies followed by amino acid mutagenesis will be
necessary to map the role of specific amino acid substitutions in the performance characteris-
tics of the PR8-A, since all the genes encoded more than one amino acid polymorphism. Nota-
bly, the unique amino acid constellations in each of the three PR8 PB1 protein lineages should
be dissected as this gene was reported to influence HA yield [14,28,29,53]. NP polymorphism
could also be significant due to its demonstrated role in virion assembly [43]. In contrast, ge-
netic analysis of performance differences between reassortant viruses with PR8-B and PR8-C
internal genes is less complex since the products of the PB2 and the M genes are identical.
These studies may also reveal the need to evaluate the potential role of non-coding nucleotide
polymorphisms, which were not analyzed in this study.
Our findings complement recent work to restore the antigen yield of A/Vietnam/1194/2004
(H5N1) 6:2R viruses by repairing an assembly defect imparting low HA content in virions
[54]. These studies showed that replacement of the transmembrane/cytoplasmic tail and non-
coding region of HA with that of PR8 substantially improved the HA content of virions
[44,54]. HA chimerization also improved the antigen yield of the A/California/7/2009 (H1N1)
pdm09 NIBRG-121 virus [11,44] by enhancing growth in eggs rather than virion HA content;
therefore, further studies are needed to determine the broad applicability of this approach.
Another study showed that the antigen yield of a 6:2R virus derived from A/Texas/05/2009
(H1N1)pdm09 viruses was increased by replacing the transmembrane domain of NA with that
of PR8 which reduced incorporation of NA and increased HA content of virions [13].
The remarkably high frequency of low antigen yield (LAY) viruses identified in the course
of this study illustrates one of the major challenges facing pandemic vaccine manufacture. This
study indicates that this risk could be mitigated in part by reassortment with PR8 backbones
from different lineages to maximize yields from candidate vaccine viruses for egg manufactur-
ing platforms. However, achieving satisfactory HA yields in manufacturing may require
screening several wiltype HA/NA surface gene donor viruses and capitalizing on adaptive
changes; which are generally selected by serial egg passage of the CVV with the most produc-
tive PR8 genes[16]. It is also worth noting that some licensed influenza vaccines that are manu-
factured in cultured cells; e.g. MDCK, also use the PR8-derived CVVs utilized for egg-based
vaccines [55]. Studies comparing growth of 6:2R viruses to parental wild-type viruses are
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needed to determine whether PR8 genes could also enhance HA yield in cell culture
vaccine manufacture.
In summary, this study identified important differences between three different PR8 virus
lineages with respect to the antigen yields of 6:2R genotype viruses in eggs. The PR8 lineages
imparting the optimal yields from 6:2R showed an association with the origin of the surface
genes and their initial HA yield. Since the subtype and lineage of the HA-NA surface genes
were major determinants of antigen yield, the parental donor virus should be carefully
evaluated.
These findings also provide a rationale for expediting development of high-yield CVV by si-
multaneously generating 6:2 reassortants with three PR8 backbones, followed by IDMS analysis
to identify the highest HA producer. Early selection of a high-yield reassortant as CVV will
likely avert the need for further optimization and speed up pandemic vaccine manufacturing.
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